Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 4/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 3/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3248164 | 0.86 | AOC3 (0.46) | SIGMAR1LMNAHTR2AHRH1AOC3 | |
| SCHEMBL1293020 | 0.79 | SIGMAR1 (0.61) | POLBALDH1A1KDM4ESIGMAR1LMNA | |
| SCHEMBL6681384 | 0.78 | POLB (0.45) | POLBALDH1A1KDM4ESIGMAR1LMNA | |
| SCHEMBL6307993 | 0.77 | UGT2B7 (0.46) | AOC3 | |
| SCHEMBL8159106 | 0.77 | POLB (0.47) | POLBALDH1A1KDM4ESIGMAR1LMNA | |
| SCHEMBL6682502 | 0.77 | POLB (0.47) | POLBALDH1A1KDM4ESIGMAR1LMNA | |
| SCHEMBL8631285 | 0.77 | KCNH2 (0.50) | SIGMAR1HTR2AOPRM1 | |
| SCHEMBL6619282 | 0.77 | LMNA (0.52) | POLBLMNAHTR2AHRH1AOC3 | |
| SCHEMBL2588402 | 0.77 | LMNA (0.52) | POLBLMNAHTR2AHRH1AOC3 | |
| SCHEMBL2321794 | 0.77 | LMNA (0.52) | POLBLMNAHTR2AHRH1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | AZEVAN PHARMACEUTICALS INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-11628160-B2 | Compositions and methods for treating brain injury | AZEVAN PHARMACEUTICALS, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-10953001-B2 | Methods for treating post traumatic stress disorder | AZEVAN PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3351104-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF INTERMITTENT EXPLOSIVE DISORDER | AZEVAN PHARMACEUTICALS INC (US) | 2020-12-09 | — | — | EP | disclosed |
| US-20200276167-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS INC (US) | 2020-09-03 | — | — | US | disclosed |
| US-20200102294-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-04-02 | — | — | US | disclosed |
| US-10364236-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2019-07-30 | — | — | US | disclosed |
| US-20190099410-A1 | METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER | AZEVAN PHARMACEUTICALS INC (US) | 2019-04-04 | — | — | US | disclosed |
| US-20080113959-A1 | {Beta}-Lactamyl vasopression V1a antagonists and methods of use | AZEVAN PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080090797-A1 | {Beta}-Lactamyl vasopression V1a antagonists and methods of use | AZEVAN PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080033165-A1 | [Beta]-Lactamyl Vasopressin V1a Antagonists and Methods of Use | KOPPEL GARY A | 2008-02-07 | — | — | US | disclosed |
| US-7268125-B2 | β-lactamyl vasopressin V1a antagonists | AZEVAN PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-20060281728-A1 | 3-Substituted beta-lactamyl vasopressin v1a antagonists | AZEVAN PHARMACEUTICALS, INC. | 2006-12-14 | — | — | US | disclosed |
| US-7119083-B2 | β-Lactamyl vasopressin V1a Antagonists | AZEVAN PHARMACEUTICALS, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-20060217364-A1 | Beta-lactamyl vasopressin V1a antagonists | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-09-28 | — | — | US | disclosed |
| WO-2006102308-A2 | BETA-LACTAMYL VASOPRESSIN V1B ANTAGONISTS | AZEVAN PHARMACEUTICALS, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2005035492-A1 | 3-SUBSTITUTED β-LACTAMYL VASOPRESSIN V1A ANTAGONISTS | SERENIX PHARMACEUTICALS, LLC. (US) | 2005-04-21 | — | — | WO | disclosed |
| US-4260776-A | PYRAZOLONE | BAYER AKTIENGESELLSCHAFT (DE) | 1981-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | POLB 3062/4885ALDH1A1 1429/4885KDM4E 3228/4885 |
| US-20190099410-A1 | METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER | GPX4, CRH, TXN | POLB 3578/4885ALDH1A1 1136/4885KDM4E 4158/4885 |
| US-20200102294-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, AVPR2, AVPR1B | POLB 3251/4885ALDH1A1 3383/4885KDM4E 4519/4885 |
| US-20080090797-A1 | {Beta}-Lactamyl vasopression V1a antagonists and methods of use | AVPR1A, AVPR2, AVPR1B | POLB 4292/4885ALDH1A1 1190/4885KDM4E 2990/4885 |
| US-20060217364-A1 | Beta-lactamyl vasopressin V1a antagonists | AVPR1A, AVPR2, AVPR1B | POLB 4385/4885ALDH1A1 1170/4885KDM4E 3653/4885 |
| US-10953001-B2 | Methods for treating post traumatic stress disorder | GPX4, CRH, TXN | POLB 3578/4885ALDH1A1 1136/4885KDM4E 4158/4885 |
| US-20060281728-A1 | 3-Substituted beta-lactamyl vasopressin v1a antagonists | AVPR1A, AVPR2, AVPR1B | POLB 4680/4885ALDH1A1 1333/4885KDM4E 3198/4885 |
| US-20200276167-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | POLB 3062/4885ALDH1A1 1429/4885KDM4E 3228/4885 |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | POLB 3251/4885ALDH1A1 3383/4885KDM4E 4519/4885 |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, AVPR2, AVPR1B | POLB 3251/4885ALDH1A1 3383/4885KDM4E 4519/4885 |
| US-20080113959-A1 | {Beta}-Lactamyl vasopression V1a antagonists and methods of use | AVPR1A, AVPR2, AVPR1B | POLB 4292/4885ALDH1A1 1190/4885KDM4E 2990/4885 |
| US-10364236-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | POLB 3251/4885ALDH1A1 3383/4885KDM4E 4519/4885 |
| US-11628160-B2 | Compositions and methods for treating brain injury | FABP7, PYGB, CHAT | POLB 3062/4885ALDH1A1 1429/4885KDM4E 3228/4885 |
| US-20080033165-A1 | [Beta]-Lactamyl Vasopressin V1a Antagonists and Methods of Use | AVPR2, AVPR1A, AVPR1B | POLB 4382/4885ALDH1A1 818/4885KDM4E 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.